Corrigendum: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma (Oncogene (2012) 32 (5089-5100) DOI: 10.1038/onc.2012.525);Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma

Oncogene

Volumn 32, Issue 42, 2013, Pages 5089-5100

  Sankar, S ^a   Bell, R ^b   Stephens, B ^a,b   Zhuo, R ^b   Sharma, S ^a   Bearss, D J ^a,b   Lessnick, S L ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Ewing sarcoma; EWS FLI; NuRD; Repression; Transcription

Indexed keywords

COREPRESSOR PROTEIN; EWS FLI FUSION PROTEIN; HISTONE DEACETYLASE; HYBRID PROTEIN; NURD PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EWING SARCOMA; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; SARCOMA CELL;

EID: 84886088733     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.142     Document Type: Erratum

References (34)

1. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165.
2. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13: 7393-7398. (Pubitemid 23354263)
3. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-2478. (Pubitemid 41540623)
4. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998; 17: 603-610. (Pubitemid 28401029)
5. Ramakrishnan R, Fujimura Y, Zou JP, Liu F, Lee L, Rao VN et al. Role of proteinprotein interactions in the antiapoptotic function of EWS-Fli-1. Oncogene 2004; 23: 7087-7094. (Pubitemid 39319170)
6. Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene. Oncogene 1995; 10: 423-431.
7. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006; 9: 405-416. (Pubitemid 43668735)
8. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24: 7275-7283. (Pubitemid 39014452)
9. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 2008; 3: e1965.
10. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res 2009; 69: 9047-9055.
11. Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23: 222-227. (Pubitemid 29455398)
12. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA 2008; 105: 10149-10154.
13. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, Dirksen U et al. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008; 44: 699-709.
14. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P et al. A molecular function map of Ewing's sarcoma. PLoS ONE 2009; 4: e5415.
15. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M et al. DNAbinding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14: 3230-3241. (Pubitemid 24132736)
16. Arvand A, Welford SM, Teitell MA, Denny CT. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Cancer Res 2001; 61: 5311-5317. (Pubitemid 32681570)
17. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci USA 1993; 90: 5752-5756. (Pubitemid 23176240)
18. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle 2006; 5: 2753-2759. (Pubitemid 44901737)
19. Gangwal K, Lessnick SL. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure. Cell Cycle 2008; 7: 3127-3132.
20. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008; 7: 250-256. (Pubitemid 351366526)
21. Owen LA, Lessnick SL. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's Sarcoma. Cell Cycle 2006; 5: 2049-2053. (Pubitemid 44553736)
22. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 2010; 11: 109-123.
23. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009; 138: 660-672.
24. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 2011; 25: 2147-2157.
25. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012; 12: 540-552.
26. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res 2012; 18: 748-757.
27. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007; 21: 1882-1894. (Pubitemid 47204928)
28. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62: 6108-6115. (Pubitemid 35244459)
29. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 505-508.
30. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 2012; 43: 1300-1307.
31. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1: 393-401. (Pubitemid 41039140)
32. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's Sarcoma. Mol Cancer Res 2006; 4: 851-859. (Pubitemid 44877015)
33. Kim J, Cantor AB, Orkin SH, Wang J. Use of in vivo biotinylation to study proteinprotein and protein-DNA interactions in mouse embryonic stem cells. Nat Protoc 2009; 4: 506-517.
34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)